Literature DB >> 20022091

Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality.

Giovanni Lughezzani1, Maxine Sun, Claudio Jeldres, Ahmed Alasker, Lars Budäus, Shahrokh F Shariat, Mathieu Latour, Hugues Widmer, Alain Duclos, Martine Jolivet-Tremblay, Francesco Montorsi, Paul Perrotte, Pierre I Karakiewicz.   

Abstract

OBJECTIVES: To compare stage at radical cystectomy (RC) and cancer-specific mortality (CSM) after RC between non-urachal adenocarcinoma (ADK) and urothelial carcinoma (UC) of the urinary bladder.
METHODS: Within 17 Surveillance, Epidemiology and End Results registries, we identified ADK and UC patients who underwent a RC between 1988 and 2006. We examined differences in stage and grade at RC between ADK and UC patients. Kaplan-Meier plots depicted CSM after RC. Cox regression analyses examined CSM rates, adjusted for T and N stages, tumor grade, age, gender, race, and year of surgery. Thereafter, we relied on statistically significant variables from the multivariate Cox regression model to match ADK and UC patients. Finally, we plotted Kaplan-Meier survival curves of the matched ADK and UC patients.
RESULTS: Of 306 ADK and 11 697 UC patients, 188 (61.4%) and 5538 (47.3%), respectively, showed extravesical disease (pT(3-4); P <.001) and 26.5% vs 21.7% had lymph node metastases at RC (P = .04), respectively. After adjustment for all covariates, including stage and grade, ADK was not associated with worse prognosis than UC (hazard ratio, 1.05; P = .6). Similarly, after matching, no difference in CSM was recorded between the 2 histologic subtypes (hazard ratio, 1.07; P = .5).
CONCLUSIONS: ADK patients undergo RC at more advanced disease stages. However, stage- and grade-adjusted CSM is the same between ADK and UC patients. Efforts should be aimed at providing definitive treatment at earlier stages, especially in patients with ADK histologic subtype. 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20022091     DOI: 10.1016/j.urology.2009.10.018

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  17 in total

Review 1.  Variant forms of bladder cancer: basic considerations on treatment approaches.

Authors:  Francesc Pons; Anna Orsola; Juan Morote; Joaquim Bellmunt
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

2.  Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab.

Authors:  Minyuen Teo; Niall C Swan; Ray S McDermott
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

3.  The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy.

Authors:  Qi Tang; Gengyan Xiong; Xuesong Li; Dong Fang; Chenguang Xi; Lei Zhang; Kaiwei Yang; Lin Yao; Cuijian Zhang; Wei Yu; Qun He; Kan Gong; Zhisong He; Liqun Zhou
Journal:  World J Urol       Date:  2015-10-24       Impact factor: 4.226

4.  Simultaneous occurrence of Meckel's diverticulum and patent urachus.

Authors:  Luit Penninga; Pieter Timmerman; Jurrian C Reurings; David R Nellensteijn
Journal:  BMJ Case Rep       Date:  2015-07-08

5.  Pathological characteristics and prognostic indicators of different histopathological types of urinary bladder cancer following radical cystectomy in a large single-center Egyptian cohort.

Authors:  Jeremy W Martin; Simone L Vernez; Yair Lotan; Ahmed Abdelhalim; Rahul Dutta; Ahmed Shokeir; Hassan Abol-Enein; Ahmed Mosbah; Mohamed Ghoneim; Ramy F Youssef
Journal:  World J Urol       Date:  2018-05-14       Impact factor: 4.226

Review 6.  Adenocarcinoma of the urinary bladder.

Authors:  Vipulkumar Dadhania; Bogdan Czerniak; Charles C Guo
Journal:  Am J Clin Exp Urol       Date:  2015-08-08

Review 7.  Characteristics and clinical significance of histological variants of bladder cancer.

Authors:  Marco Moschini; David D'Andrea; Stephan Korn; Yasin Irmak; Francesco Soria; Eva Compérat; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

Review 8.  Molecular and histopathology directed therapy for advanced bladder cancer.

Authors:  Constantine Alifrangis; Ursula McGovern; Alex Freeman; Thomas Powles; Mark Linch
Journal:  Nat Rev Urol       Date:  2019-07-09       Impact factor: 14.432

9.  Trends of incidence and prognosis of primary adenocarcinoma of the bladder.

Authors:  Haowen Lu; Weidong Zhu; Weipu Mao; Feng Zu; Yali Wang; Wenchao Li; Bin Xu; Lihua Zhang; Ming Chen
Journal:  Ther Adv Urol       Date:  2021-05-24

10.  Metastatic Adenocarcinoma of the Bladder Presenting as Malignant Pleural Effusion: A Rare Presentation of Bladder Adenocarcinoma.

Authors:  Rekha Ravikumar; Astrid Ross; Muhammad S Khan; Ghazal Khan; Shaili Desai
Journal:  Cureus       Date:  2021-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.